Akynzeo Approval History
- FDA approved: Yes (First approved October 10th, 2014)
- Brand name: Akynzeo
- Generic name: netupitant and palonosetron
- Company: Eisai Inc.
- Treatment for: Nausea/Vomiting, Chemotherapy Induced
Akynzeo (netupitant and palonosetron) is an oral NK1 receptor antagonist and 5-HT3 receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Development History and FDA Approval Process for Akynzeo
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.